Migraine-specific Preventive Therapies Can Be a Primary Care Tool, Leading Investigator Says

"These newer [migraine] therapies are geared for primary care. Their side effect profile is fantastic...they're easy to use...and primary care providers are very comfortable with monoclonal antibodies," said migraine specialist and researcher Jessica Ailani, MD, while speaking with Patient Care.

In the rest of our conversation, captured below, Ailani discussed the remarkable results some migraine patients are experiencing with the calcitonin gene-related peptide inhibitors and other new targeted drug classes as well as the opportunities for effective primary care-specialist cotreatment.

Jessica Ailani, MD, is professor of clinical neurology and director of Medstar Georgetown Headache Center at the MedStar Georgetown University Hospital in Washington, DC.